Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

EMEA Requests Stronger Liver Disorder Warnings For Ketek

This article was originally published in The Pink Sheet Daily

Executive Summary

The European Medicines Agency has asked Sanofi-Aventis to revise product labeling for its antibiotic Ketek (telithromycin) to include stronger warnings about liver disorders

You may also be interested in...



Ketek Risk Cannot Be Distinguished From Class, FDA Says

Labeling for Sanofi-Aventis’ macrolide antibiotic telithromycin increases warnings about liver toxicity and myasthenia gravis.

Ketek Risk Cannot Be Distinguished From Class, FDA Says

Labeling for Sanofi-Aventis’ macrolide antibiotic telithromycin increases warnings about liver toxicity and myasthenia gravis.

Sanofi-Aventis Voluntarily Pauses Ketek Pediatric Trials Pending FDA Consultation

The decision to stop pediatric studies of the antibiotic was not at FDA’s request or due to safety concerns, the company says.

Related Content

Topics

UsernamePublicRestriction

Register

LL1133990

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel